Special Issue

Biomedical Properties, Developments and Therapeutic Potential of Sesquiterpenoid Lactones and Natural Compounds

Message from the Guest Editors

The development of new strategies and treatments from natural compounds offers the opportunity to provide benefits such as to reduce incidence, prevalence, or mortality for a wide range of chronic or degenerative diseases. Natural compounds, for example, sesquiterpene lactones, have shown properties such as neurodegeneration preventive, analgesic, antimigraine, sedative, phytotoxic, antiprotozoal, antibacterial and anti-tumor. However, there are still many natural compounds that are currently used only in traditional medicine and that have pharmacological properties. such as antidiabetic, antimicrobial, antioxidant, antiarthritic, cardioprotective, hepatoprotective, nephroprotective, fibrinolytic and healing. These compounds can be studied extensively to develop new treatments for a wide variety of diseases. In this Special Issue, we aim to entice research experts in the field of therapeutic agents and strategies, to publish discoveries, developments and the future implementation of new therapies pertaining to the use of sesquiterpene lactones and of all possible natural compounds.

Guest Editors

Dr. Normand Garcia-Hernandez

Dr. Rosa Ordoñez Razo

Dr. Israel Ramírez-Sánchez

Deadline for manuscript submissions

closed (25 July 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/196873

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

